55052-27-2

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-1H-pyrrolo[2,3-b]pyridine is used as a key intermediate compound for the synthesis of various heterocyclic compounds. These heterocyclic compounds are further utilized in the development of drugs for the treatment of cancer.
Application Reason:
The unique chemical structure of 6-chloro-1H-pyrrolo[2,3-b]pyridine allows it to be a versatile building block in the synthesis of heterocyclic compounds with potential anticancer properties. By incorporating 6-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE into the molecular structure of new drugs, researchers can explore its potential to target specific cancer-related pathways and develop more effective treatments for various types of cancer.

InChI:InChI=1/C7H5ClN2/c8-6-2-1-5-3-4-9-7(5)10-6/h1-4H,(H,9,10)

Upstream product

• 143468-07-9 6-Chloro-1-methoxycarbonyl-1H-pyrrolo<2,3-b>pyridine 
• 271-63-6 7-Azaindole 
• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 849068-50-4 ethyl 6-chloro-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 143468-11-5 1-Benzoyl-6-chloro-1H-pyrrolo<2,3-b>pyridine 

Downstream Products

• 351438-94-3 6-phenyl-1H-pyrrolo[2,3-b]pyridine 
• 902134-77-4 4-(6-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)butan-2-one 
• 383875-59-0 6-chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxaldehyde 
• 915140-96-4 6-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid 
• 896722-50-2 1-benzenesulfonyl-6-chloro-1H-pyrrolo[2,3-b]pyridine 
• 1248587-69-0 N-(3-fluorophenyl)-N-methyl-1H-pyrrolo[2,3-b]pyridin-6-amine 
• 934568-25-9 6-chloro-1-methyl-1H-pyrrolo[2,3-b]pyridine 
• 1202502-83-7 6-chloro-1-[2-(3,4-dimethoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridine 
• 1202502-85-9 ethyl 3-[1-[2-(3,4-dimethoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-6-yl]benzoate 
• 1202502-87-1 3-[1-[2-(3,4-dimethoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-6-yl]benzoic acid 
• 896722-51-3 1-benzenesulfonyl-6-methyl-1H-pyrrolo[2,3-b]pyridine 
• 824-51-1 6-methyl-1H-pyrrolo<2,3-b>pyridine 
• 220896-14-0 6-chloro-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 
• 1296200-79-7 N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide 

Relevant academic research and scientific papers

COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES

The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases

Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors

Multiple lines of evidence have indicated that pyruvate kinase M2 (PKM2) is upregulated in most cancer cells and it is increasingly recognized as a potential therapeutic target in oncology. In a continuation of our discovery of lead compound 5 and SAR study, the 7-azaindole moiety in compound 5 was systematically optimized. The results showed that compound 6f, which has a difluoroethyl substitution on the 7-azaindole ring, exhibited high PKM2 activation potency and anti-proliferation activities on A375 cell lines. In a xenograft mouse model, oral administration of compound 6f led to significant tumor regression without obvious toxicity. Further mechanistic studies revealed that 6f could influence the translocation of PKM2 into nucleus, as well as induction of apoptosis and autophagy of A375 cells. More importantly, compound 6f significantly inhibited migration of A375 cells in a concentration-dependent manner. Collectively, 6f may serve as a lead compound in the development of potent PKM2 activators for cancer therapy.

Preparation method of drug composition for treating febrile convulsion in children

The invention relates to a preparation method of a drug composition for treating febrile convulsion in children. The method comprises a route as shown in the specification. A treatment mechanism of the drug of the invention is to prolong the convulsion latency of a febrile convulsion patient, shorten the convulsion duration, relieve the convulsion seriousness, inhibit apoptosis of hippocampal neurons, regulate the levels of GABA and Glu, relieve the cerebral injury of febrile convulsion patient and finally achieve the purpose of treating the febrile convulsion.

ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

Synthetic method of 6-chloro-7-azaindole

The invention discloses a synthetic method of 6-chloro-7-azaindole, belonging to the field of chemical synthesis. 7-azaindole is taken as a raw material, and the 6-chloro-7-azaindole is synthesized by three actions of N-oxidation, chlorination and hydrolysis. The process route is optimized, and the yield is improved by 70% or more, and is improved by 7% compared with the prior art. The improved synthetic route is simple to operate and feasible, the economic benefits are effectively improved, and large-scale industrial promotion is facilitated.

NEW CRTH2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

New CRTh2 antagonists

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

ANTICANCER AGENT

An anticancer agent comprising a compound represented by the formula (I) [R1 represents hydrogen atom, hydroxyl group, a C1-6alkoxy group and the like; R2 and R3 represents hydrogen atom, a halogen atom, a C1-6alkyl group and the like; R4 represents hydrogen atom, a C1-6alkyl group, a C1-6alkylsulfonyl group and the like; R5 represents hydrogen atom or a substituent; .... represents a single bond or a double bond; R6 and R7 represents hydrogen atom, a C1-6alkyl group and the like; R8 represents hydrogen atom, a C1-6alkyl group and the like; A represents -O-, -S-, or - CH2-; D represents -C= or -N=; X represents methylene group, -O-, or -CO-; Q represents -N= or -C(R8)=; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.

Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I)

Rho kinase (ROCK) inhibitors are potential therapeutic agents to treat disorders such as hypertension, multiple sclerosis, cancers, and glaucoma. Here, we disclose the synthesis, optimization, biological evaluation of potent indole and 7-azaindole based ROCK inhibitors that have high potency on ROCK (IC 50 = 1 nM) with 740-fold selectivity over PKA (47). Moreover, 47 showed very good DMPK properties making it a good candidate for further development. Finally, docking studies with a homology model of ROCK-II were performed to rationalize the binding mode of these compounds and showed the compounds bound in both orientations to take advantage to H-bonds with Lys-121 of ROCK-II.

Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents

Utilizing scaffold-hopping drug-design strategy, we sought to identify a backup drug candidate for BPR0L075 (1), an indole-based anticancer agent. For this purpose, 5,6-fused bicyclic heteroaromatic scaffolds were designed and synthesized through shufflin